On April 13, 2016 Celprogen reported they successfully completed their pre-clinical evaluation of CEP1430 and CEP1507 compounds as selectively targeting Pancreatic Cancer stem Cell population that contribute to treatment related resistance (Press release, Celprogen, APR 13, 2016, View Source [SID:1234510892]). Both compounds demonstrated growth inhibition of pancreatic tumors in patient derived xenograft (PDX) cancer models by 80% to 85%. The results of the study will be presented in an abstract format on Monday, April 18, 2016 at American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in New Orleans. These compounds are Celprogen’s propriety compounds for targeting Pancreatic Cancer Stem Cells (CSC) and Circulating Tumor Cells (CTC) in patients with advanced stages of pancreatic cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The present invention relates to Drug Discovery programs at Celprogen that identify potential drug candidates for the treatment of pancreatic cancer. At present Celprogen is exploring partnership with Pharmaceutical Industry to move promising drug candidates forward to the clinical development and increasing the armament of drugs against pancreatic cancer. CEP1430 is a selective inhibitor of CSC that can be administrated orally and does not exhibit sign of toxicity. The mechanism of cell death also indicates that these molecules will greatly enhance the efficacy of immune based approaches to improve outcome in pancreatic cancer patients. These pancreatic Stem Cell selective inhibitors are expected to eradicate tumors, improve quality of life and prolong and/or overall survival and patients bearing pancreatic tumors.